Ticker

This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.

Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.